معرفی
Professor Paul I Welsh is a Professor of Molecular Epidemiology at the University of Glasgow, affiliated with the BHF Glasgow Cardiovascular Research Centre. He completed a BSc in Immunology at the University of Glasgow and a PhD investigating inflammatory biomarkers and cardiovascular disease (CVD) under Prof Gordon Lowe. He holds a MSc in Epidemiology from the London School of Hygiene and Tropical Medicine (2014), where he earned a distinction and the 150th Anniversary Prize. His research focuses on cardiovascular and metabolic health, particularly leveraging biomarkers like natriuretic peptides and cardiac troponins to improve patient care. He leads the Glasgow Biomarker Research Unit (GlasBRU), conducting assays in blood, urine, and saliva for studies such as the British Regional Heart Study and UK Biobank. Notable contributions include work on the DAPA-HF and SUGAR-DM-HF clinical trials, and his team’s involvement in seminal observational studies. Awards include BHF fellowships (2010, 2013), a Readership (2019), and a Chair (2023).
- Education: BSc Immunology (Glasgow), PhD (Glasgow Royal Infirmary), MSc Epidemiology (LSHTM)
- Affiliations: BHF Glasgow Cardiovascular Research Centre, University of Glasgow
- Roles: Lead of GlasBRU, Trustee of Scottish Heart and Arterial disease Risk Prevention (SHARP)
Research Interests: Paul’s work spans cardiovascular epidemiology, biomarker discovery, and metabolic disease. He investigates how biomarkers like NT-proBNP and high-sensitivity troponin can refine disease prediction and guide treatments. His team explores associations between biomarkers, lifestyle, and clinical outcomes in large cohorts. Recent focus includes the impact of therapies like empagliflozin on heart failure and the role of lipoprotein(a) in cardiovascular risk.
Articles Trends: Recent studies emphasize biomarker utility in risk stratification (e.g., cardiac troponins), drug effects (dapagliflozin, tirzepatide), and socioeconomic factors influencing treatment adherence. His work often integrates proteomics and genetic data to uncover novel pathways linking mental health, inflammation, and CVD.
- Awards: BHF Advanced Training Fellowship (2010), BHF Intermediate Basic Scientist Fellowship (2013), Readership (2019), Chair (2023), MSc Distinction/150th Anniversary Prize (2014)
Advising/Grants: Leads major studies like DiRECT and STANDby. Collaborates on risk scores (ASSIGN version 2.0) and global initiatives (UK Biobank). Active in clinical trials (DAPA-HF, EMPRESS-MI).
Labs/Teams: Glasgow Biomarker Research Unit (GlasBRU), part of the BHF Centre. Involved in multi-disciplinary teams for cardiovascular and metabolic studies.